Human thymosin alpha protogene mutant synthesis, expression and use

Application Number: 00107954
Application Date: 2000.06.01
Publication Number: 1326947
Publication Date: 2001.12.19
Priority Information:
International: C07K14/435;C12N15/63;C12N15/64;A61K38/17;A61P1/16;A61P35/00;A61P37/00
Applicant(s) Name: Shuanglu Pharmaceutical Co., Ltd., Beijing
Inventor(s) Name: Xu Mingbo;Wang Yongbo;Huang Xiangdong
Patent Agency Code: 00000
Patent Agent:
Abstract By utilizing the facultative agency of genetic code, coliform bacteria favorable codon is designed, GC content in DNA sequence in reduced Pro T alpha DNA sequence is synthesized. PCR amplified human Pro T alpha gene and protocaryon expression vector, such as pBV220, are assembled into high efficiency expression plasmid, converted coliform bacteria are expressed with temperature induced Pro T alpha gene with a expression amount up to 20-25 % of total thallus protein. The engineering bacteria are fermentation amplified and crushed then maintain supernatant. The supernatant is heat treated, anionic exchanged and chromatographic treated and gel chromatographic purified to obtain purified product. The purified product is mixed with protective agent to prepare freeze dried preparation for the treatment of human immunodeficiency disease, viral hepatitis and cancer.